The potential impact of vaccination on the prevalence of gonorrhea

Vaccine

Volumn 33, Issue 36, 2015, Pages 4520-4525

  Craig, Andrew P ^a   Gray, Richard T ^a   Edwards, Jennifer L ^b   Apicella, Michael A ^c   Jennings, Michael P ^d   Wilson, David P ^a   Seib, Kate L ^d  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d GRIFFITH UNIVERSITY   (Australia)

Author keywords

Antimicrobial resistance; Epidemiological simulation model; Gonorrhea; Neisseria gonorrhoeae; Vaccine

Indexed keywords

BACTERIAL VACCINE; GONORRHEA VACCINE; UNCLASSIFIED DRUG;

ARTICLE; GONORRHEA; HETEROSEXUALITY; HUMAN; NEISSERIA GONORRHOEAE; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; SEXUAL BEHAVIOR; SIMULATION; VACCINATION; ADOLESCENT; ADULT; COMPUTER SIMULATION; DISEASE TRANSMISSION; FEMALE; IMMUNOLOGY; MALE; MIDDLE AGED; PREVENTION AND CONTROL; TRANSMISSION; YOUNG ADULT;

ADOLESCENT; ADULT; BACTERIAL VACCINES; COMPUTER SIMULATION; DISEASE TRANSMISSION, INFECTIOUS; FEMALE; GONORRHEA; HUMANS; MALE; MIDDLE AGED; NEISSERIA GONORRHOEAE; PREVALENCE; YOUNG ADULT;

EID: 84939562411     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.07.015     Document Type: Article

References (54)

1. WHO Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae (2012) 2012, World Health Organization (WHO), Department of Reproductive Health and Research, Available from 〈http://www.who.int/reproductivehealth/publications/rtis/9789241503501/en/〉.
2. Unemo M., Shafer W.M. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future. Clin Microbiol Rev 2014, 27:587-613.
3. CDC Antibiotic Resistance Threats in the United States, 2013 2013, Available from 〈http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf〉.
4. Tapsall J. Antibiotic resistance in Neisseria gonorrhoeae is diminishing available treatment options for gonorrhea: some possible remedies. Expert Rev Anti Infect Ther 2006, 4:619-628.
5. Kirkcaldy R.D., Weinstock H.S., Moore P.C., Philip S.S., Wiesenfeld H.C., Papp J.R., et al. The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea. Clin Infect Dis 2014, 59:1083-1091.
6. Tapsall J.W., Ndowa F., Lewis D.A., Unemo M. Meeting the public health challenge of multidrug- and extensively drug-resistant Neisseria gonorrhoeae. Expert Rev Anti Infect Ther 2009, 7:821-834.
7. Jerse A.E., Deal C.D. Vaccine research for gonococcal infections: where are we?. Sex Transm Infect 2013, 89(Suppl. 4):iv63-iv-L68.
8. Handsfield H.H., Lipman T.O., Harnisch J.P., Tronca E., Holmes K.K. Asymptomatic gonorrhea in men. Diagnosis, natural course, prevalence and significance. N Engl J Med 1974, 290:117-123.
9. Hook E.W., Hansfield H.H. Gonoccoal infection in the adult. Sexually tramsitted diseases 2008, 627-645. McGraw-Hill, New York, NY. K.K. Holmes (Ed.).
10. Farley T.A., Cohen D.A., Elkins W. Asymptomatic sexually transmitted diseases: the case for screening. Prev Med 2003, 36:502-509.
11. Johnson L.F., Alkema L., Dorrington R.E. A Bayesian approach to uncertainty analysis of sexually transmitted infection models. Sex Transm Infect 2010, 86:169-174.
12. WHO Prevalence and incidence of selected sexually transmitted infections. Chlamydia trachomatis, Neisseria gonorrhoeae, syphilis and Trichomonas vaginalis. Methods and results used by WHO to generate 2005 estimates 2011, World Health Organisation, Available from 〈http://www.who.int/reproductivehealth/publications/rtis/9789241502450/en/〉.
13. Edwards J.L., Apicella M.A. The molecular mechanisms used by Neisseria gonorrhoeae to initiate infection differ between men and women. Clin Microbiol Rev 2004, 17:965-981.
14. Sweet R.L., Blankfort-Doyle M., Robbie M.O., Schacter J. The occurrence of chlamydial and gonococcal salpingitis during the menstrual cycle. JAMA 1986, 255:2062-2064.
15. Levine W.C., Pope V., Bhoomkar A., Tambe P., Lewis J.S., Zaidi A.A., et al. Increase in endocervical CD4 lymphocytes among women with nonulcerative sexually transmitted diseases. J Infect Dis 1998, 177:167-174.
16. Cohen M.S., Hoffman I.F., Royce R.A., Kazembe P., Dyer J.R., Daly C.C., et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. AIDSCAP Malawi Research Group. Lancet 1997, 349:1868-1873.
17. Chen A., Boulton I.C., Pongoski J., Cochrane A., Gray-Owen S.D. Induction of HIV-1 long terminal repeat-mediated transcription by Neisseria gonorrhoeae. AIDS 2003, 17:625-628.
18. Eng T.R., Butler W.T. The Hidden Epidemic: Confronting Sexually Transmitted Diseases. Committee on Prevention and Control of Sexually Transmitted Diseases 1997, 1-488. National Academies Press, Washington, DC.
19. Gray R.T., Beagley K.W., Timms P., Wilson D.P. Modeling the impact of potential vaccines on epidemics of sexually transmitted Chlamydia trachomatis infection. J Infect Dis 2009, 199:1680-1688.
20. WHO Global incidence and prevalence of selected curable sexually transmitted infections-2008 2012, Available from 〈http://www.who.int/reproductivehealth/publications/rtis/stisestimates/en/〉.
21. Fox K.K., Thomas J.C., Weiner D.H., Davis R.H., Sparling P.F., Cohen M.S. Longitudinal evaluation of serovar-specific immunity to Neisseria gonorrhoeae. Am J Epidemiol 1999, 149:353-358.
22. Schmidt K.A., Schneider H., Lindstrom J.A., Boslego J.W., Warren R.A., Van de Verg L., et al. Experimental gonococcal urethritis and reinfection with homologous gonococci in male volunteers. Sex Transm Dis 2001, 28:555-564.
23. Ross J.D., Moyes A., Young H. Serovar specific immunity to Neisseria gonorrhoeae: does it exist?. Genitourin Med 1995, 71:367-369.
24. Hosenfeld C.B., Workowski K.A., Berman S., Zaidi A., Dyson J., Mosure D., et al. Repeat infection with Chlamydia and gonorrhea among females: a systematic review of the literature. Sex Transm Dis 2009, 36:478-489.
25. Holmes K.K., Johnson D.W., Trostle H.J. An estimate of the risk of men acquiring gonorrhea by sexual contact with infected females. Am J Epidemiol 1970, 91:170-174.
26. Hooper R.R., Reynolds G.H., Jones O.G., Zaidi A., Wiesner P.J., Latimer K.P., et al. Cohort study of venereal disease. I: the risk of gonorrhea transmission from infected women to men. Am J Epidemiol 1978, 108:136-144.
27. Platt R., Rice P.A., McCormack W.M. Risk of acquiring gonorrhea and prevalence of abnormal adnexal findings among women recently exposed to gonorrhea. JAMA 1983, 250:3205-3209.
28. Lin J.S., Donegan S.P., Heeren T.C., Greenberg M., Flaherty E.E., Haivanis R., et al. Transmission of Chlamydia trachomatis and Neisseria gonorrhoeae among men with urethritis and their female sex partners. J Infect Dis 1998, 178:1707-1712.
29. Rappuoli R. Bridging the knowledge gaps in vaccine design. Nat Biotechnol 2007, 25:1361-1366.
30. Mietzner T.A., Thomas C.E., Hobbs M.M., Cohen M.S. Vaccines against gonoccoal infection. New generation vaccines 2004, 755-773. Marcel Dekker, Inc, New York, NY. Third Edition Revised and Expanded ed. J.B. Kaper, R. Rappouli, M.A. Liu, M.F. Good (Eds.).
31. Jerse A.E., Bash M.C., Russell M.W. Vaccines against gonorrhea: current status and future challenges. Vaccine 2014, 32:1579-1587.
32. Seib K.L., Rappuoli R. Difficulties in developing neisserial vaccines. Neisseria: molecular mechanisms of pathogenesis 2010, 195-226. Horizon Scientific Press, Norwich, UK. C.A. Genco, L.M. Wetzler (Eds.).
33. Liu Y., Feinen B., Russell M.W. New concepts in immunity to Neisseria gonorrhoeae: innate responses and suppression of adaptive immunity favor the pathogen, not the host. Front Microbiol 2011, 2:52.
34. Rinaudo C.D., Telford J.L., Rappuoli R., Seib K.L. Vaccinology in the genome era. J Clin Invest 2009, 119:2515-2525.
35. Ali H., Donovan B., Wand H., Read T.R., Regan D.G., Grulich A.E., et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ: Br Med J 2013, 346:f2032.
36. CDC Sexually transmitted diseases surveillance 2013 2014, Centers for Disease Control and Prevention, Available from: 〈http://www.cdc.gov/std/stats13/default.htm〉.
37. Yorke J.A., Hethcote H.W., Nold A. Dynamics and control of the transmission of gonorrhea. Sex Transm Dis 1978, 5:51-56.
38. Cohen M.S., Cannon J.G., Jerse A.E., Charniga L.M., Isbey S.F., Whicker L.G. Human experimentation with Neisseria gonorrhoeae: rationale, methods, and implications for the biology of infection and vaccine development. J Infect Dis 1994, 169:532-537.
39. Garnett G.P. The theoretical impact and cost-effectiveness of vaccines that protect against sexually transmitted infections and disease. Vaccine 2014, 32:1536-1542.
40. Paul P., Fabio A. Literature review of HPV vaccine delivery strategies: considerations for school- and non-school based immunization program. Vaccine 2014, 32:320-326.
41. Garland S.M. The Australian experience with the human papillomavirus vaccine. Clin Ther 2014, 36:17-23.
42. WHO Rubella vaccines: WHO position paper. Wkly Epidemiol Rec 2011, 86:301-316.
43. WHO BCG vaccine. WHO position paper. Wkly Epidemiol Rec 2004, 79:27-38.
44. Colditz G.A., Berkey C.S., Mosteller F., Brewer T.F., Wilson M.E., Burdick E., et al. The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 1995, 96:29-35.
45. WHO Tetanus vaccine, WHO position paper. Wkly Epidemiol Rec 2006, 81:198-208.
46. Roberts-Witteveen A., Pennington K., Higgins N., Lang C., Lahra M., Waddell R., et al. Epidemiology of gonorrhoea notifications in Australia, 2007-12. Sex Health 2014, 11:324-331.
47. Mayer K.H. Sexually transmitted diseases in men who have sex with men. Clin Infect Dis 2011, 53(Suppl. 3):S79-S83.
48. Bissessor M., Tabrizi S.N., Fairley C.K., Danielewski J., Whitton B., Bird S., et al. Differing Neisseria gonorrhoeae bacterial loads in the pharynx and rectum in men who have sex with men: implications for gonococcal detection, transmission, and control. J Clin Microbiol 2011, 49:4304-4306.
49. Quinn T.C., Wawer M.J., Sewankambo N., Serwadda D., Li C., Wabwire-Mangen F., et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000, 342:921-929.
50. Wilson D.P., Law M.G., Grulich A.E., Cooper D.A., Kaldor J.M. Relation between HIV viral load and infectiousness: a model-based analysis. Lancet 2008, 372:314-320.
51. Bleeker M.C.G., Hogewoning C.J.A., Berkhof J., Voorhorst F.J., Hesselink A.T., van Diemen P.M., et al. Concordance of specific human papillomavirus types in sex partners is more prevalent than would be expected by chance and is associated with increased viral loads. Clin Infect Dis 2005, 41:612-620.
52. Gambhir M., Basáñez M.-G., Turner F., Kumaresan J., Grassly N.C. Trachoma: transmission, infection, and control. Lancet Infect Dis 2007, 7:420-427.
53. Gallo M.F., Macaluso M., Warner L., Fleenor M.E., Hook E.W., Brill I., et al. Bacterial vaginosis, gonorrhea, and chlamydial infection among women attending a sexually transmitted disease clinic: a longitudinal analysis of possible causal links. Ann Epidemiol 2012, 22:213-220.
54. Saigh J.H., Sanders C.C., Sanders W.E. Inhibition of Neisseria gonorrhoeae by aerobic and facultatively anaerobic components of the endocervical flora: evidence for a protective effect against infection. Infect Immun 1978, 19:704-710.